Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
AVUV vs XBI: how they differ
AVUV and XBI hold 1% of their weight in the same names, and XBI returned more over the year.
Avantis U.S. Small Cap Value ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, AVUV and XBI hold 1% of their money in the same securities at the same weight.
| Holding | AVUV | XBI |
|---|---|---|
| Catalyst Pharmaceuticals Inc | 0.48% | 0.88% |
| Monte Rosa Therapeutics Inc | 0.12% | 0.48% |
| Emergent BioSolutions Inc | 0.08% | 0.13% |
| Rigel Pharmaceuticals Inc | 0.07% | 0.24% |
| MiMedx Group Inc | 0.00% | 0.11% |
| Only in AVUV | Only in XBI |
|---|---|
| Viasat Inc 1.39% | Apogee Therapeutics Inc 1.49% |
| Matson Inc 0.98% | Moderna Inc 1.41% |
| Lear Corp 0.90% | Twist Bioscience Corp 1.41% |
| SM Energy Co 0.86% | Oruka Therapeutics Inc 1.38% |
| Avnet Inc 0.86% | Kymera Therapeutics Inc 1.36% |
| Macy's Inc 0.78% | Viking Therapeutics Inc 1.31% |
| StoneX Group Inc 0.77% | Praxis Precision Medicines Inc 1.29% |
| Five Below Inc 0.72% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| AVUV Avantis U.S. Small Cap Value ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Avantis | State Street |
| What it is | U.S. Small Cap Value | SPDR S&P Biotech |
| Total return, 1 year | +24.6% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +7.2 pts | +46.5 pts |
| Expense ratio | 0.25% | 0.35% |
| Already in the S&P 500 | 0.0% | 8.5% |
| Holdings | 795 | 150 |
AVUV in plain words
AVUV is an index equity fund tracking the U.S. Small Cap Value. Over the year to Sep 11, 2026 it returned +24.6% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.25% a year. By its holdings filed for May 31, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 795 positions, with the top ten at 8.7%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, AVUV or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, AVUV returned +24.6% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, AVUV or XBI?
- AVUV charges 0.25% a year and XBI charges 0.35%, so AVUV is cheaper. Fees come from each fund's prospectus.
- How much do AVUV and XBI overlap with the S&P 500?
- By their latest filed holdings, 0% of AVUV and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 1% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, AVUV against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/AVUV-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources